Pazopanib

Specifications

444731-52-6CAS Number

963-764-2EC Number

5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamideIUPAC Name

C21H23N7O2SChemical Formula

437.5 g/molMolecular Weight

Pazopanib; 444731-52-6; GW786034; 5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide; pazopanibum; DTXSID8048733; 7RN5DR86CK; NSC-752782; GW780604; GW-780604; 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide; DTXCID1028659; CHEBI:71219; Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-; 5-({4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide; Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-; RefChem:55812; Votrient; 790713-33-6; GW-786034; MFCD11616589; 5-[4-[(2,3-Dimethyl-2H-indazol-6-yl)-methyl-amino]-pyrimidin-2-ylamino]-2-methyl-benzenesulfonamide; 5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide; GW 78603; GW 786034; C21H23N7O2S; 5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide; NCGC00188865-01; 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide; 5-[[4-[(2,3-dimethyl-2h-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide; Pazopanib [INN]; CAS-444731-52-6; Pazopanib [INN:BAN]; UNII-7RN5DR86CK; Pazopanib?; HSDB 8210; Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-; 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide; 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide; GW 786034; Pazopanib; Votrient; Pazopanib (Standard); GW 786034B; indazolylpyrimidine 13; Pazopanib (free base); Kinome_3790; PAZOPANIB [MI]; PAZOPANIB [VANDF]; PAZOPANIB [WHO-DD]; Pazopanib (GW786034); PAZOPANIB [EMA EPAR]; 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; SCHEMBL588608; Pazopanib - Bio-X trade mark; CHEMBL477772; GTPL5698; JMC514632 Compound 13; orb1225034; orb1310940; SCHEMBL29392503; BDBM26474; BDBM31091; cid_10113978; CUIHSIWYWATEQL-UHFFFAOYSA-N; GLXC-90392; HMS3244C21; HMS3244C22; HMS3244D21; HMS3656L14; HMS3745G05; HMS5081I04; EX-A1241; Tox21_113174; EBC-12617; HY-10208R; NSC752782; NSC800839; s3012; T0097L; AKOS005145819; Tox21_113174_1; AC-8522; CCG-265010; CS-0269; DB06589; FD26771; NSC 752782; NSC-800839; SB17290; SDCCGSBI-0647656.P002; NCGC00188865-02; NCGC00188865-03; NCGC00188865-10; NCGC00188865-20; AS-11066; BD164238; BP-44038; HY-10208; SY067128; A3022; NS00070516; SW218082-3; EN300-57325; P-6706; SBI-0647656.0001; AB01273967-01; AB01273967-02; AB01273967_05; AB01273967_06; AR-270/43507999; Q7157043; BRD-K74514084-001-03-9; BRD-K74514084-003-02-7; BRD-K74514084-003-09-2; Z1541638525; 5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]-2-pyrimidinyl}amino)-2-methylbenzenesulfonamide; 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]-pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamideSynonyms